Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment

BACKGROUND: Crizotinib is an approved tyrosine kinase inhibitor in the treatment of advanced-stage non-small-cell lung cancer patients with anaplastic lymphoma receptor tyrosine kinase (ALK) rearrangement. Renal dysfunction after crizotinib administration was recently reported, but the physiopatholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosoux, Adeline, Duplaquet, Fabrice, Ocak, Sebahat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567074/
https://www.ncbi.nlm.nih.gov/pubmed/28868009
http://dx.doi.org/10.1159/000475755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567074/
https://www.ncbi.nlm.nih.gov/pubmed/28868009
http://dx.doi.org/10.1159/000475755

Ejemplares similares